ITB Med
Pre-clinicalThe lifelong need for immunosuppression after transplantation negatively affects both patient health and the transplanted organ. ITB-MED’s novel therapy aims to provide immunosuppression freedom, potentially leading to better outcomes, improved quality of life, and reduced healthcare costs.
Founded
2015
Focus
Biologics
About
The lifelong need for immunosuppression after transplantation negatively affects both patient health and the transplanted organ. ITB-MED’s novel therapy aims to provide immunosuppression freedom, potentially leading to better outcomes, improved quality of life, and reduced healthcare costs.
Funding History
2Total raised: $10.5M
Series A$8MUndisclosedApr 15, 2022
Seed$2.5MUndisclosedSep 15, 2020
Company Info
TypePrivate
Founded2015
LocationStockholm, Sweden
StagePre-clinical
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile